Clinical study for pyrrotinib combined with or without trastuzumab in the treatment of advanced her2-positive colorectal cancer

ABSTRACT: Interventions: Pyrrotinib combined with trastuzumab:oral Pyrrotib maleate tablets, initial dose 400 mg/day, taken within 30 min after breakfast, once a day, continuous administration, 21 days per cycle. Trastuzumab for injection: intravenous infusion with an initial loading dose of 8mg/kg followed by 6mg/kg. The first infusion takes approximately 90 minutes.;Pyrrotinib alone:Oral Pyrrotib maleate tablets by initial dose of 400 mg/day, taken within 30 min after breakfast, once a day, continuous administration, 21 days per treatment cycle. Primary outcome(s): objective response rate Study Design: Non randomized control

DISEASE(S): Her2-positive Advanced Colorectal Cancer

PROVIDER: 2689432 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR